Activating mutations in the N- and K-ras oncogenes differentially affect the growth properties of the IL-6-dependent myeloma cell line ANBL6

Cancer Research

Volumn 57, Issue 11, 1997, Pages 2268-2275

  Billadeau, Daniel ^a   Liu, Pocheng ^a   Jelinek, Diane ^c   Shah, Nisha ^a,b   LeBien, Tucker W ^a,b   Van Ness, Brian ^a,b  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL POPULATION; DISEASE COURSE; DNA SYNTHESIS; GENE MUTATION; GENETIC DISORDER; GENETIC TRANSDUCTION; HUMAN; HUMAN CELL; MYELOMA CELL; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; TUMOR GROWTH;

APOPTOSIS; BONE MARROW CELLS; CELL CYCLE; CELL DIVISION; CELLS, CULTURED; DNA; GENES, RAS; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-6; MULTIPLE MYELOMA; MUTATION; RECOMBINATION, GENETIC; STROMAL CELLS; TRANSDUCTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 0030926355     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (44)

1. Hunter, T. Cooperation between oncogenes. Cell, 64: 249-270, 1991.
2. Bos, J. L. The ras gene family and human carcinogenesis. Mutat. Res., 195: 255-271, 1988.
3. Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Nakamura, Y., White, R., Smits, A. M., and Bos, J. L. Genetic alterations during colorectal tumor development. N. Engl. J. Med., 319: 525-532, 1988.
4. Corradini, P., Ladetto, M., Voena, C., Palumbo, A., Inghirami, G., Knowlcs, D. M., Boccadoro, M., and Pileri, A. Mutational activation of N-and K-ras oncogenes in plasma cell dyscrasias. Blood, 81: 2708-2713, 1993.
5. Lowy, D. R., and Willumsen, B. M. Functions and regulation of RAS. Annu. Rev. Biochem., 62: 851-891, 1993.
6. Ahuja, H. G., Foti, A., Bar, E. M., and Cline, M. J. The pattern of mutational involvement of RAS genes in human hematologic malignancies determined by DNA amplification and direct sequencing. Blood, 75: 1684-1690, 1990.
7. Bos, J. L. Ras oncogenes in hematopoietic malignancies. Hematol. Pathol., 2: 55-63, 1988.
8. Neri, A., Knowles, D. M., Greco, A., McCormick, F., and Dalla-Favera, R. Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc. Natl. Acad. Sci. USA, 85: 9268-9272, 1988.
9. Paquette, R. L., Berenson, J., Lichtenstein, A., McCormick, F., and Koeffler, H. P. Oncogenes in multiple myeloma: point mutation of N-ras. Oncogene, 5: 1659-1663, 1990.
10. Neri, A., Murphy, J. P., Cro, L., Ferrero, D., Tarella, C. Baldini, L., and Dalla-Favera. R. Ras oncogene mutation in multiple myeloma. J. Exp. Med., 170: 1715-1725, 1989.
11. Portier, M., Moles, J. P., Mazars, G. R., Jeanteur, P., Bataille, R., Klein, B., and Theillet, C. p53 and RAS gene mutations in multiple myeloma. Oncogene, 7: 2539-2543, 1992.
12. Liu, P., Quam, L., Billadeau, D., Kay, N., Greipp, P., Kyle, R., Oken, M. M., Leong, T., and Van Ness, B. Activating mutations of N-and K-ras in multiple myeloma show distinct clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III trial. Blood, 88: 2699-2706, 1996.
13. Corradini, P., Ladetto, M., Inghirami, G., Boccadoro, M., and Pileri, A. N-and K-ras oncogenes in plasma cell dyscrasias. Leuk. Lymphoma, 15: 17-20, 1994.
14. Skorski, T., Szczylik, C., Ratajczak, M. Z., Malaguarnera, L., Gewirtz, A. M., and Calabretta, B. Growth factor-dependent inhibition of normal hematopoiesis by N-ras antisense oligodeoxynucleotides. J. Exp. Med., 175: 743-750, 1992.
15. Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., Kuramoto, A., and Kishimoto, T. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (Lond.), 332: 83-85, 1988.
16. Nakafuku, M. Satoh, T., and Kaziro, Y. Differentiation factors, including nerve growth factor, fibroblast growth factor, and interleukin 6. induce an accumulation of an active Ras-GTP complex in rat pheochromocytoma PC12 cells. J. Biol. Chem., 267: 19448-19454, 1992.
17. Dumenil, D., Neel, H., Lacout, C., and Dautry, F. Infection with a Kirsten retrovirus can induce a multiplicity of tumorigenic phenotypes in the interleukin 3-dependent FDC-P1 cells. Exp. Hematol., 22: 178-185, 1994.
18. Nair, A. P., Diamantis, I. D., Conscience, J. F., Kindler, V., Hofer, P., and Moroni, C. A v-H-ras-dependent hemopoietic tumor model involving progression from a clonal stage of transformation competence to autocrine interleukin 3 production. Mol. Cell. Biol., 9: 1183-1190, 1989.
19. Uemura, N., Ozawa, K., Tojo, A., Takahashi, K., Okano, A., Karasuyama, H., Tani, K., and Asano, S. Acquisition of interleukin 3 independence in FDC-P2 cells after transfection with the activated c-H-ras gene using a bovine papillomavirus-based plasmid vector. Blood, 12: 3198-3204, 1992.
20. Maher, J., Baker. D. A., Dibb, N. J., and Roberts, I. A. G. N-, H-, and K-ras: a difference in transforming potential. Blood, 84a: 1167, 1994.
21. Yang-Yen, H. F., Chambard, J. C. Sun, Y. C., Smeal, T., Schmidt, T. J., Droin, J., and Karin, M. Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction. Cell, 62: 1205-1215, 1990.
22. Schule, R., Rangarajan, P., Kliewer, S., Ranson, L. J., Bolado, J., Yang, N., Verma, I. M., and Evans, R. M. Functional antagonism between oncoprotein c-Jun and the glucocorticoid receptor. Cell, 62: 1217-1226, 1990.
23. Lichtenstein, A., Tu, Y., Fady, C., Vescio, R., and Berenson, J. Interleukin 6 inhibits apoptosis of malignant plasma cells. Cell. Immunol., 162: 248-255, 1995.
24. Jelinek, D. F., Ahmann, G. J., Greipp, P. R., Jalal, S. M., Westendorf, J. J., Katzmann, J. A., Kyle, R. A., and Lust, J. A. Coexistence of aneuploid subclones within a myeloma cell line that exhibits clonal immunoglobulin gene rearrangement: clinical implications. Cancer Res., 53: 5320-5327, 1993.
25. Billadeau, D., Jelinek, D. F., Shah, N., LeBien, T. W., and Van Ness, B. Introduction of an activated N-ras oncogene alters the growth characteristics of the interleukin 6-dependent myeloma cell line ANBL6. Cancer Res., 55: 3640-3646, 1995.
26. Miller, A. D., and Rosman, G.J. Improved retroviral vectors for gene transfer and expression. Biotechniques, 7: 980-982, 1989.
27. Corsaro, C. M., and Pearson, M. L. Enhancing the efficiency of DNA-mediated gene transfer in mammalian cells. Somatic Cell Genet., 7: 603-616, 1981.
28. Wolf, M. L., Buckley, J. A., Goldfarb, A., Law, C. L., and LeBien, T. W. Development of a bone marrow culture for maintenance and growth of normal human B-cell precursors. J. Immunol., 147: 3324-3330, 1991.
29. Dittel, B. N., McCarthy, J. B., Wayner, E. A., and LeBien, T. W. Regulation of human B-cell precursor adhesion to bone marrow stromal cells by cytokines that exert opposing effects on the expression of vascular cell adhesion molecule-1 (VCAM-1). Blood, 81: 2272-2282, 1993.
30. Larson, A. W., and LeBien, T. W. Cross-linking CD40 on human B-cell precursors inhibits or enhances growth depending on the stage of development and the IL costimulus. J. Immunol., 153: 584-594, 1994.
31. Nicoletti, I., Migliorati, G., Pagliacci, M. C., Grignani, F., and Riccardi, C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J. Immunol. Methods, 139: 271-279, 1991.
32. Darzynkiewicz, Z., Bruno, S., Del, B. G., Gorczyca, W., Hotz, M. A., Lassota, P., and Traganos, F. Features of apoptotic cells measured by flow cytometry. Cytometry, 13: 795-808, 1992.
33. Corradini, P., Inghirami, G., Astolfi, M., Ladetto, M., Voena, C., Ballerini, P., Gu, W., Nilsson, K., Knowles, D. M. Inactivation of tumor suppressor genes. p53 and Rb1, in plasma cell dyscrasias. Leukemia (Baltimore), 8: 758-767, 1994.
34. Dao, D., Sawyer, J., Epstein, J., Hoover, R., Barlogie, B., and Tricot, G. Deletion of the retinoblastoma gene in multiple myeloma. Leukemia (Baltimore), 8: 1280-1284, 1994.
35. Tanaka, K., Takechi, M., Asaoku, H., Dohy, H., and Kamada, N. A high frequency of N-ras oncogene mutations in multiple myeloma. Int. J. Hematol., 56: 119-127, 1992.
36. Winston, J. T., Cats, S. R., Wang, Y. Z., and Pledger, W. J. Regulation of the cell cycle machinery by oncogenic ras. Oncogene, 12: 127-134, 1996.
37. Cleveland, J. L., Troppmair, J., Packham, G., Askew, D. S., Lloyd, P., Gonzalez. G. M., Nunez, G., Ihle, J. N., and Rapp, U. R. v-raf suppresses apoptosis and promotes growth of interleukin 3-dependent myeloid cells. Oncogene, 9: 2217-2226, 1994.
38. McCormick, F. Activators and effectors of ras21 proteins. Curr. Opin. Genet. Dev., 4: 71-76, 1994.
39. Polakis, P., and McCormick, F. Structural requirements for the interaction of p21 ras with GAP, exchange factors, and its biological effector target. J. Biol. Chem., 268: 9157-9160, 1993.
40. McCormick, F. Raf: the holy grail of Ras biology. Trends Cell Biol., 4: 347-350, 1994.
41. Maher, J., Hawisa, S., Manning, M., and Roberts, I. A. G. Functional differences between the RAS isoforms: mutational analysis. Blood, 86: 2925, 1995.
42. Seiden, M. V., and Anderson, K. C. Multiple myeloma. Curr. Opin. Oncol., 6: 41-49, 1994.
43. Klein, B., Wijdness, J., Zhang, X-G., Jourdan, M., Boiron, J-M., Brochier, J., Liautard, J., Merlin, M., Clement, C., Morel-Fournier, B., Lu, Z-Y., Mannoni, P., Sany, J., and Bataille, R. Murine anti-interleukin 6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood, 78: 1198-1204, 1991.
44. Suzuki, H., Yasukawa, K., Saito, T., Goitsuka, R., Hasegawa, A., Ohsugi, Y., Taga, T., and Kishimoto, T. Anti-human interleukin 6 receptor antibody inhibits human myeloma growth in vivo. Eur. J. Immunol., 22: 1989-1993, 1992.